Myriad Genetics (MYGN)

• Market cap: $804M
• 1 day: -0.79%
• 5 days: -9.74%
• 1 month: -15.30%
• 3 months: -34.81%
• 6 months: -67.44%
• Year to date: -34.81%
• 1 year: -58.96%
• 5 years: -32.88%
• 10 years: -74.69%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1,343% more call options, than puts

Call options by funds: $4.1M | Put options by funds: $284K

25% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 73

0.96% more ownership

Funds ownership: 100.51% [Q3] → 101.47% (+0.96%) [Q4]

11% less funds holding

Funds holding: 246 [Q3] → 218 (-28) [Q4]

45% less first-time investments, than exits

New positions opened: 31 | Existing positions closed: 56

49% less capital invested

Capital invested by funds: $2.5B [Q3] → $1.27B (-$1.23B) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 25% upside
• Avg. target: $17.72 101% upside
• High target: $29 230% upside

9 analyst ratings

• positive: 5 56%
• neutral: 3 33%
• negative: 1 11%

Scotiabank Sung Ji Nam 12% 1-year accuracy 3 / 25 met price target	127% upside $20	Sector Outperform Maintained	1 Apr 2025
Piper Sandler Dave Weiner 0 / 0 met price target	42% upside $12.50	Overweight Upgraded	12 Mar 2025
B of A Securities Derik De Bruin 35% 1-year accuracy 7 / 20 met price target	25% upside $11	Underperform Maintained	3 Mar 2025
Raymond James Andrew Cooper 13% 1-year accuracy 2 / 16 met price target	116% upside $19	Outperform Reiterated	25 Feb 2025
UBS Lu Li 0% 1-year accuracy 0 / 3 met price target	82% upside $16	Neutral Maintained	25 Feb 2025